Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01881763 · ClinicalTrials.gov registry record · Phase 4
Ketamine as an Augmentation Strategy for Electroconvulsive Therapy (ECT) in Depression
A Phase 4 study, sponsored by Northwell Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 31
- Enrollment target
NCT01881763: Completed Phase 4 study, sponsored by Northwell Health.
NCT01881763 is a Phase 4 study that has completed, run by Northwell Health. The registered enrollment target is 31 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01881763, a Phase 4 study, has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 31 participants
- Enrollment target
Study Summary
The study aims to compare outcomes of Electroconvulsive Therapy (ECT) using ketamine versus methohexital anesthesia in depressed patients. The investigators hypothesize that patients who receive ketamine anesthesia during ECT will achieve remission status faster than those receiving methohexital anesthesia. Also, at the end of the ECT course subjects will display fewer cognitive side effects compared to those treated with methohexital anesthesia.
Primary Outcome
The items mostly range from a score of 0-4 but there are some questions that range from a score of 0-2. The maximum total score that can be reported is 76 and the lowest score is 0. Higher values represent a worse outcome. Items are summed together to compute the total score. Remission is defined as two consecutive Hamilton Rating Scale for Depression, 24 items (HRSD-24) scores \< 10, and HRSD-24 total score does not increase \> 3 points on the second consecutive HRSD-24, or remains \< 6 at the
Interventions
- DRUG Ketamine
- DRUG Methohexital
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2010-06 |
| Est. Completion | 2017-07 |
| Phase | Phase 4 |
What the finished NCT01881763 record still lists
NCT01881763 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which Ketamine is the first listed.
NCT01881763 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01881763 about?
NCT01881763 is a clinical study titled "Ketamine as an Augmentation Strategy for Electroconvulsive Therapy (ECT) in Depression". The study aims to compare outcomes of Electroconvulsive Therapy (ECT) using ketamine versus methohexital anesthesia in depressed patients. The investigators hypothesize that patients who receive ketamine anesthesia during ECT will achieve remission status faster than those receiving methohexital ane...
What is the current status of trial NCT01881763?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 31 participants. The study started on 2010-06. Estimated completion is 2017-07.
What interventions are being tested in trial NCT01881763?
The interventions under investigation include: Ketamine (DRUG), Methohexital (DRUG).
Who is sponsoring clinical trial NCT01881763?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01881763's enrollment target sits among peer trials
31 1544th of 2000 higher than 449 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia